Title: Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostate
Authors: RIZVI S.m.a.ALLEN B.j.LEE C.s.BRUCHERTSEIFER FrankMORGENSTERN AlfredAPOSTOLIDIS ChristosCLARKE R.a.
Citation: IMMUNOTHERAPY vol. 4 no. 5 p. 1-6
Publisher: FUTURE MEDICINE LTD
Publication Year: 2012
JRC N°: JRC70139
ISSN: 1750-743X
URI: http://www.futuremedicine.com/doi/abs/10.2217/imt.12.42?journalCode=imt
http://publications.jrc.ec.europa.eu/repository/handle/JRC70139
Type: Articles in Journals
Abstract: Tumour growth requires development of new blood vessels – a process known as angiogenesis. The anti-angiogenic monoclonal antibody Bevacizumab (BZ), which targets vascular endothelial growth factor (VEGF), is now part of the standard treatment for advanced colorectal cancer. Castrate resistant prostate cancers also express VEGF but are only marginally responsive to BZ alone or in combination with chemotherapy. Targeted alpha-radioimmunotherapy (TAT) is an emerging technology that can safely enhance immunotherapy for improved cancer control. TAT targeting can be further enhanced through orthotopic delivery. In this preliminary study we investigate orthotopic TAT for the control of early-stage prostate cancer PC3 xenografts using alpha radio-labelled BZ (213Bi-BZ). Results indicate that orthotopic administration of 213Bi- BZ greatly improves the early control of organ confined prostate cancer compared to BZ alone (P<0.01).
JRC Institute:Institute for Transuranium Elements

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.